PL3404102T3 - Koniugaty do dostarczania do kości i sposób ich wykorzystania do nakierowywania białek na kość - Google Patents

Koniugaty do dostarczania do kości i sposób ich wykorzystania do nakierowywania białek na kość

Info

Publication number
PL3404102T3
PL3404102T3 PL18173111T PL18173111T PL3404102T3 PL 3404102 T3 PL3404102 T3 PL 3404102T3 PL 18173111 T PL18173111 T PL 18173111T PL 18173111 T PL18173111 T PL 18173111T PL 3404102 T3 PL3404102 T3 PL 3404102T3
Authority
PL
Poland
Prior art keywords
bone
amino acid
same
target proteins
delivery conjugates
Prior art date
Application number
PL18173111T
Other languages
English (en)
Inventor
Philippe Crine
Guy Boileau
Isabelle Lemire
Thomas P. Loisel
Original Assignee
Alexion Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharmaceuticals, Inc. filed Critical Alexion Pharmaceuticals, Inc.
Publication of PL3404102T3 publication Critical patent/PL3404102T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C12N9/6494—Neprilysin (3.4.24.11), i.e. enkephalinase or neutral-endopeptidase 24.11
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24011—Neprilysin (3.4.24.11), i.e. enkephalinase or neutral endopeptidase 24.11
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03001—Alkaline phosphatase (3.1.3.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PL18173111T 2004-04-21 2005-04-21 Koniugaty do dostarczania do kości i sposób ich wykorzystania do nakierowywania białek na kość PL3404102T3 (pl)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US56382804P 2004-04-21 2004-04-21
US59034704P 2004-07-23 2004-07-23
US61498404P 2004-10-04 2004-10-04
EP11000196.3A EP2348114B1 (en) 2004-04-21 2005-04-21 Bone delivery conjugates and method of using same to target proteins to bone
EP05739065A EP1759001B1 (en) 2004-04-21 2005-04-21 Bone delivery conjugates and method of using same to target proteins to bone
EP18173111.8A EP3404102B1 (en) 2004-04-21 2005-04-21 Bone delivery conjugates and method of using same to target proteins to bone
PCT/CA2005/000615 WO2005103263A1 (en) 2004-04-21 2005-04-21 Bone delivery conjugates and method of using same to target proteins to bone

Publications (1)

Publication Number Publication Date
PL3404102T3 true PL3404102T3 (pl) 2021-12-13

Family

ID=35196985

Family Applications (3)

Application Number Title Priority Date Filing Date
PL11000196T PL2348114T3 (pl) 2004-04-21 2005-04-21 Koniugaty do dostarczania do kości i sposób ich wykorzystania do nakierowywania białek na kość
PL05739065T PL1759001T3 (pl) 2004-04-21 2005-04-21 Koniugaty dostarczane do kości i sposób ich zastosowania do nakierowywania białek do kości
PL18173111T PL3404102T3 (pl) 2004-04-21 2005-04-21 Koniugaty do dostarczania do kości i sposób ich wykorzystania do nakierowywania białek na kość

Family Applications Before (2)

Application Number Title Priority Date Filing Date
PL11000196T PL2348114T3 (pl) 2004-04-21 2005-04-21 Koniugaty do dostarczania do kości i sposób ich wykorzystania do nakierowywania białek na kość
PL05739065T PL1759001T3 (pl) 2004-04-21 2005-04-21 Koniugaty dostarczane do kości i sposób ich zastosowania do nakierowywania białek do kości

Country Status (14)

Country Link
US (5) US7763712B2 (pl)
EP (3) EP3404102B1 (pl)
JP (1) JP4874954B2 (pl)
AT (1) ATE505551T1 (pl)
AU (1) AU2005235635B2 (pl)
CA (1) CA2559228C (pl)
DE (1) DE602005027461D1 (pl)
DK (3) DK2348114T3 (pl)
ES (3) ES2687786T3 (pl)
HU (2) HUE055861T2 (pl)
PL (3) PL2348114T3 (pl)
PT (3) PT1759001E (pl)
SI (2) SI2348114T1 (pl)
WO (1) WO2005103263A1 (pl)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060014697A1 (en) * 2001-08-22 2006-01-19 Travis Mickle Pharmaceutical compositions for prevention of overdose or abuse
HUE055861T2 (hu) 2004-04-21 2021-12-28 Alexion Pharma Inc Csontbejuttató konjugátumok és azok alkalmazási módszere fehérjék csonthoz kötéséhez
US7863238B2 (en) 2004-06-10 2011-01-04 Saint Louis University Proteins with an attached short peptide of acidic amino acids
US20070081984A1 (en) 2005-10-11 2007-04-12 Shunji Tomatsu Compositions and methods for treating hypophosphatasia
US7972593B2 (en) 2004-06-10 2011-07-05 Saint Louis University Delivery of therapeutic agents to the bone
US7825217B2 (en) * 2006-09-15 2010-11-02 University Of Kansas Medical Center Polypeptides for bone mineralization
ES2675174T3 (es) 2007-04-09 2018-07-09 The Board Of Trustees Of The University Of Arkansas Proteínas de fusión de un dominio de enlazamiento a colágeno y hormona paratiroidea
PL2158319T4 (pl) * 2007-05-11 2016-04-29 Alexion Pharma Inc Fosfataza alkaliczna kierowana do kości, zestawy i zastosowanie
WO2011113027A2 (en) 2010-03-12 2011-09-15 Synageva Biopharma Corp Npp1 fusion proteins
BR112012027765A2 (pt) 2010-04-30 2019-09-24 Enobia Pharma Inc métodos, composições e kits para tratamento de distúrbios de mineralização da matriz.
US9266939B2 (en) 2010-12-27 2016-02-23 Alexion Pharmaceuticals, Inc. Compositions comprising natriuretic peptides and methods of use thereof
SG11201401605QA (en) 2011-10-19 2014-09-26 Alexion Pharma Holding Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
WO2013120060A1 (en) 2012-02-09 2013-08-15 The Board Of Trustees Of The University Of Arkansas Delivery of therapeutic agents by a collagen binding protein
DK3391899T3 (da) 2011-12-14 2020-08-24 Univ Arkansas Afgivelse af terapeutiske midler ved hjælp af et kollagenbindende protein
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
WO2016007873A1 (en) 2014-07-11 2016-01-14 The Regents Of The University Of Michigan Compositions and methods for treating craniosynostosis
CA2967851C (en) 2014-12-05 2024-02-27 Alexion Pharmaceuticals, Inc. Treating seizure with recombinant alkaline phosphatase
AU2016211447B2 (en) 2015-01-28 2021-09-23 Alexion Pharmaceuticals, Inc. Methods of treating a subject with an alkaline phosphatase deficiency
EP3337894A1 (en) * 2015-08-17 2018-06-27 Alexion Pharmaceuticals, Inc. Manufacturing of alkaline phosphatases
US20200231652A1 (en) 2015-08-31 2020-07-23 National Research Council Of Canada Tgf-b-receptor ectodomain fusion molecules and uses thereof
JP6868617B2 (ja) 2015-09-28 2021-05-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド 低ホスファターゼ血症の組織非特異的アルカリホスファターゼ（ｔｎｓａｌｐ）酵素補充療法に有効な投薬計画の特定
US11400140B2 (en) 2015-10-30 2022-08-02 Alexion Pharmaceuticals, Inc. Methods for treating craniosynostosis in a patient
US11065306B2 (en) 2016-03-08 2021-07-20 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children
EP3454913A4 (en) 2016-03-15 2019-11-27 The Regents of the University of California BONE OBTAINING ANTIBODY CONJUGATE AND METHOD FOR THE PRODUCTION AND USE THEREOF
WO2017173395A1 (en) 2016-04-01 2017-10-05 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
KR20220162816A (ko) 2016-04-01 2022-12-08 알렉시온 파마슈티칼스, 인코포레이티드 알칼리성 포스파타아제로 근육 약화의 치료
US10988744B2 (en) 2016-06-06 2021-04-27 Alexion Pharmaceuticals, Inc. Method of producing alkaline phosphatase
EP3474886B1 (en) 2016-06-27 2021-08-04 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children and adolescents
WO2018035420A1 (en) 2016-08-18 2018-02-22 Alexion Pharmaceuticals, Inc. Methods for treating tracheobronchomalacia
WO2018102616A1 (en) * 2016-11-30 2018-06-07 Purdue Research Foundation Fracture targeted bone regeneration through parathyroid hormone receptor stimulation
AR110755A1 (es) 2017-01-20 2019-05-02 Genzyme Corp Anticuerpos dirigidos a hueso
TW202506185A (zh) 2017-01-20 2025-02-16 法商賽諾菲公司 抗TGF-β抗體及其用途
WO2018148573A1 (en) 2017-02-10 2018-08-16 The Board Of Trustees Of The University Of Arkansas Collagen-binding agent compositions and methods of using the same
JP7231553B2 (ja) 2017-03-02 2023-03-01 ナショナル リサーチ カウンシル オブ カナダ Ｔｇｆ－ｂ－受容体外部ドメイン融合分子及びその使用
JP2020512363A (ja) * 2017-03-31 2020-04-23 アレクシオン ファーマシューティカルズ， インコーポレイテッド 成人及び青年における低ホスファターゼ症（ｈｐｐ）を治療する方法
WO2019067502A1 (en) 2017-09-27 2019-04-04 Alexion Pharmaceuticals, Inc. METHODS FOR IMPROVING CARDIOVASCULAR FUNCTION AND TREATING CARDIOVASCULAR DISEASE USING RECOMBINANT ECTO-NUCLEOTIDE PYROPHOSPHATASE / PHOSPHODIESTERASE
MX2020006890A (es) * 2018-01-02 2020-09-07 Cedars Sinai Medical Center Nanoparticulas para la administracion dirigida de polipeptidos terapeuticos.
EP3737750B1 (en) 2018-01-09 2024-06-05 Theriva Biologics, Inc. Alkaline phosphatase agents for treatment of neurodevelopmental disorders
ES3032290T3 (en) 2018-03-20 2025-07-16 Theriva Biologics Inc Intestinal alkaline phosphatase formulations
WO2019183209A1 (en) 2018-03-20 2019-09-26 Synthetic Biologics, Inc. Alkaline phosphatase agents for treatment of radiation disorders
JP2021519590A (ja) 2018-03-30 2021-08-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド 糖タンパク質の製造
US20210214408A1 (en) 2018-05-30 2021-07-15 Purdue Research Foundation Targeting anabolic drugs for accelerated fracture repair
WO2020033867A2 (en) 2018-08-10 2020-02-13 Alexion Pharmaceuticals, Inc. Methods of treating neurofibromatosis type 1 and related conditions with alkaline phosphatase
AU2020270046B2 (en) 2019-05-06 2026-02-05 Theriva Biologics, Inc. Alkaline phosphate-based oncology treatments
JP7796645B2 (ja) 2019-12-09 2026-01-09 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼポリペプチド及びその使用方法
EP4084819A1 (en) 2020-01-03 2022-11-09 The United States of America, as represented by the Secretary, Department of Health and Human Services Tnap locally administered for promoting periodontal health
WO2022014697A1 (ja) * 2020-07-17 2022-01-20 国立大学法人広島大学 ペプチド、ペプチドの塩、医薬組成物及び生体組織石灰化抑制剤
KR20230117327A (ko) * 2020-09-03 2023-08-08 어빈 에스.와이. 첸 가용성 알칼리성 포스파타제 작제물 및 가용성 알칼리성 포스파타제 작제물을 인코딩하는 폴리뉴클레오티드를 포함하는 발현 벡터
CA3173631A1 (en) 2021-02-12 2022-08-18 Walter C. Voegtli Alkaline phosphatase polypeptides and methods of use thereof
US12403179B2 (en) 2021-02-18 2025-09-02 The Board Of Trustees Of The University Of Arkansas Release of growth factors at wound healing stages
CA3262218A1 (en) 2022-07-19 2024-01-25 Rampart Bioscience, Inc. CIRCULAR NON-IMMUNOGENEOUS NON-VIRAL DNA VECTORS

Family Cites Families (179)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1538678A (en) * 1923-02-24 1925-05-19 Joseph S Blinn Suppository injector
US3791385A (en) * 1972-10-16 1974-02-12 A Davis Catamenial device and applicator thereof
CA1339210C (en) 1988-05-31 1997-08-05 John Lewicki Recombinant techniques for production of novel natriuretic and vasodilator peptides
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US6406697B1 (en) 1989-02-23 2002-06-18 Genentech, Inc. Hybrid immunoglobulins
US6541610B1 (en) 1989-09-05 2003-04-01 Immunex Corporation Fusion proteins comprising tumor necrosis factor receptor
DE69108830T2 (de) 1990-04-20 1995-09-14 Hisayuki Matsuo Neue im schwein vorkommende physiologisch aktive peptide.
JP3026351B2 (ja) 1990-07-13 2000-03-27 壽之 松尾 ブタｃｎｐ遺伝子及び前駆体蛋白
JP2930380B2 (ja) 1990-07-13 1999-08-03 壽之 松尾 ブタ由来新規生理活性ペプチド（ｃｎｐ―５３）
JP2977159B2 (ja) 1990-09-07 1999-11-10 壽之 松尾 カエル由来新規生理活性ペプチド（カエルｃｎｐ）
JP2977158B2 (ja) 1990-09-07 1999-11-10 壽之 松尾 トリ由来新規生理活性ペプチド（ニワトリｃｎｐ）
JP3026352B2 (ja) 1990-09-11 2000-03-27 壽之 松尾 ラットＣＮＰｃＤＮＡ及び前駆体蛋白
JP3026354B2 (ja) 1990-09-27 2000-03-27 壽之 松尾 ヒトｃｎｐ遺伝子及び前駆体蛋白
JP2809533B2 (ja) 1991-01-31 1998-10-08 壽之 松尾 Ｃｎｐ類似体ペプチド
AU662155B2 (en) 1991-05-10 1995-08-24 Celtrix Pharmaceuticals, Inc. Targeted delivery of bone growth factors
AU6360394A (en) 1993-03-03 1994-09-26 Mayo Foundation For Medical Education And Research Vasonatrin peptide and analogs thereof
WO1995005455A1 (en) * 1993-08-13 1995-02-23 Rijksuniversiteit Te Groningen Pharmaceutical composition comprising phosphatase or a derivative thereof
ES2194895T3 (es) 1993-11-12 2003-12-01 Genentech Inc Peptidos natriureticas atriales especifico de un receptor.
US6525022B1 (en) 1993-11-12 2003-02-25 Genentech, Inc. Receptor specific atrial natriuretic peptides
US5846932A (en) 1993-11-12 1998-12-08 Genentech, Inc. Receptor specific atrial natriuretic peptides
US5665704A (en) 1993-11-12 1997-09-09 Genentech, Inc. Receptor specific atrial natriuretic peptides
JPH10500969A (ja) 1994-06-02 1998-01-27 ベーリンガー マンハイム ゲゼルシャフト ミット ベシュレンクテル ハフツング カルジオジラチンフラグメントの調製方法、高度に精製されたカルジオジラチンフラグメント及びそれらの調製のための中間生成物類
JPH0870875A (ja) 1994-09-05 1996-03-19 Tosoh Corp 組換えアルカリフォスファタ−ゼ融合タンパク質
US5863782A (en) * 1995-04-19 1999-01-26 Women's And Children's Hospital Synthetic mammalian sulphamidase and genetic sequences encoding same
US6028055A (en) 1996-10-22 2000-02-22 Genetech, Inc. Receptor selective BNP
EP0939770A1 (en) 1996-10-22 1999-09-08 Genentech, Inc. Receptor specific brain natriuretic peptide (bnp)
WO2000053755A2 (en) 1999-03-08 2000-09-14 Genentech, Inc. Compositions and methods for the treatment of tumor
US6455495B1 (en) * 1997-02-14 2002-09-24 The Salk Institute For Biological Studies Methods and compositions for delivery of therapeutic agents to bone tissue employing conjugates of negatively charged peptide oligomers with therapeutic agents
JP4394279B2 (ja) 1998-03-09 2010-01-06 ジーランド ファーマ アクティーゼルスカブ 酵素加水分解に対する傾向が減少した薬理学的に活性なペプチド複合体
CA2245903A1 (en) * 1998-09-28 2000-03-28 Mcgill University Use of pex in the treatment of metabolic bone diseases
CA2260376A1 (en) 1999-02-11 2000-08-11 Universite De Montreal New metalloproteases of the neprilysin family
CA2262056A1 (en) * 1999-02-24 2000-08-24 Guy Boileau Composition, methods and reagents for the synthesis of a soluble form of human pex
JP2002542304A (ja) 1999-04-28 2002-12-10 ベクトレイムド インコーポレイテッド 酵素的に活性化された重合薬物接合体
US6887470B1 (en) 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US20040266673A1 (en) 2002-07-31 2004-12-30 Peter Bakis Long lasting natriuretic peptide derivatives
US6849714B1 (en) 1999-05-17 2005-02-01 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
SI1105409T1 (sl) 1999-05-17 2006-06-30 Conjuchem Inc Zascita endogenih peptidov pred peptidazno ucinkovitostjo s konjugacijo na krvne komponente
JP2000327583A (ja) * 1999-05-17 2000-11-28 Medei Sci Puraningu:Kk 骨指向性ホルモン誘導体
DE19942230C2 (de) 1999-09-03 2003-09-25 Wolf-Georg Forssmann Verwendung natriuretischer Peptide als antibiotisch wirksame Subsanzen zur Behandlung von bakteriellen Infektionen
ATE360082T1 (de) 1999-11-16 2007-05-15 Genzyme Corp Vektoren und transgene mit regulatorischen elementen zur genverabreichung in leber
WO2001044257A1 (en) * 1999-12-17 2001-06-21 Ariad Pharmaceuticals, Inc. Proton pump inhibitors
US6407211B1 (en) 1999-12-17 2002-06-18 Mayo Foundation For Medical Education And Research Chimeric natriuretic peptides
JP4237375B2 (ja) 2000-03-31 2009-03-11 アスビオファーマ株式会社 虚血性疾患の処置又は予防に用いる医薬組成物
US20050142217A1 (en) 2000-04-26 2005-06-30 Adams Michael A. Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
IL152428A0 (en) 2000-04-26 2003-05-29 Univ Kingston Formulations and method of using nitric oxide mimetics against a malignant cell phenotype
US7678391B2 (en) 2000-04-26 2010-03-16 Queen's University At Kingston Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
EP1502604A1 (en) 2000-04-26 2005-02-02 Cellegy Pharmaceuticals, Inc Use of nitric oxide mimetics in cancer treatment
US6830885B1 (en) 2000-08-18 2004-12-14 Phenogene Therapeutiques Inc. Nucleic acid molecule, method and kit for selecting a nucleic acid having a desired feature
DE60123635T2 (de) * 2000-08-23 2007-08-16 Enobia Pharma Inc., Montreal Methode und zusammensetzung zur förderung von osteogenese
US6436386B1 (en) * 2000-11-14 2002-08-20 Shearwater Corporation Hydroxyapatite-targeting poly (ethylene glycol) and related polymers
UA93662C2 (uk) 2000-12-07 2011-03-10 Эли Лилли Энд Компани Гетерологічний пептидильований глюкагон-подібний білок та його застосування для виготовлення лікарського засобу для лікування пацієнтів, що страждають на ожиріння або інсулінонезалежний цукровий діабет
JP2002178279A (ja) 2000-12-12 2002-06-25 Ulvac Japan Ltd 基板搬送方法
WO2002068579A2 (en) 2001-01-10 2002-09-06 Pe Corporation (Ny) Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof
JP2002246704A (ja) 2001-02-16 2002-08-30 Philips Japan Ltd 電子装置及び回路装置
IL142118A0 (en) 2001-03-20 2002-03-10 Prochon Biotech Ltd Method and composition for treatment of skeletal dysplasias
US7888372B2 (en) * 2001-03-23 2011-02-15 National Institutes Of Health (Nih) Compositions and methods for modulating bone mineral deposition
WO2002092020A2 (en) * 2001-03-23 2002-11-21 The Burnham Institute Compositions and methods for modulating bone mineral deposition
US6808905B2 (en) * 2001-05-14 2004-10-26 Cell Genesys, Inc. Lentiviral vectors encoding clotting factors for gene therapy
AU2002367839A1 (en) 2001-07-16 2003-11-17 Hk Pharmaceuticals, Inc. Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions
US6610025B2 (en) * 2001-08-06 2003-08-26 The Procter & Gamble Company Tampon applicator arrangement
BRPI0203172B8 (pt) 2001-09-28 2021-05-25 Nakao Kazuwa composição farmacêutica para acondroplasia
US20050202442A1 (en) 2003-12-15 2005-09-15 Morris David W. Novel therapeutic targets in cancer
DE60239763D1 (de) 2001-12-20 2011-05-26 Enobia Pharma Inc Knochenpolypeptid-1
ES2425738T3 (es) 2001-12-21 2013-10-17 Human Genome Sciences, Inc. Proteínas de fusión de la albúmina
US20080194481A1 (en) 2001-12-21 2008-08-14 Human Genome Sciences, Inc. Albumin Fusion Proteins
US20030158132A1 (en) * 2002-01-22 2003-08-21 Genvec, Inc. Method for enhancing bone density or formation
JP2005527510A (ja) 2002-03-06 2005-09-15 セレジー ファーマシューティカルズ インコーポレーティッド 癌の治療において一酸化窒素模倣体を使用するための製剤および方法
US20050113286A1 (en) 2002-03-18 2005-05-26 Schreiner George F. Methods for treating congestive heart failure
US20040077537A1 (en) 2002-03-18 2004-04-22 Schreiner George F. Method for treating congestive heart failure
IL149562A0 (en) 2002-05-09 2002-11-10 Prochon Ltd Fgf variants and methods for use thereof
CA2433479A1 (en) * 2002-07-22 2004-01-22 F. Hoffmann-La Roche Ag Conjugate of a tissue non-specific alkaline phosphatase and dextran, process for its production and use thereof
EP1530588A2 (en) 2002-07-31 2005-05-18 Conjuchem, Inc. Long lasting natriuretic peptide derivatives
US20060110359A1 (en) 2002-09-06 2006-05-25 Juan Sanchez-Ramos Cellular delivery of natriuretic peptides
EP1562990B1 (en) 2002-11-18 2010-07-21 Syn X Pharma, Inc. Polyclonal-monoclonal elisa assay for detecting n-terminus probnp
US7648962B2 (en) 2002-11-26 2010-01-19 Biocon Limited Natriuretic compounds, conjugates, and uses thereof
EP1569683B1 (en) 2002-11-26 2010-03-03 Biocon Limited Modified natriuretic compounds, conjugates, and uses thereof
WO2004050620A2 (en) 2002-12-03 2004-06-17 Enobia Pharma Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex
US20060172929A1 (en) 2003-01-13 2006-08-03 Gudrun Rappold-Hoerbrand Use of natriuretic peptides for the treatment of stature disorders related to the shox gene
CA2516128A1 (en) 2003-02-14 2004-09-02 Sagres Discovery, Inc. Therapeutic targets in cancer
US7488713B2 (en) 2004-03-18 2009-02-10 University Of South Florida Cancer treatment using C-type natriuretic peptides
EP1616181B1 (en) 2003-04-17 2009-08-12 Vermillion, Inc. Polypeptides related to natriuretic peptides and methods of their identification and use
CA2527878A1 (en) * 2003-05-30 2005-01-27 Alexion Pharmaceuticals, Inc. Antibodies and fusion proteins that include engineered constant regions
DE602004030342D1 (de) 2003-06-17 2011-01-13 Otago Innovation Ltd Beurteilung des skelettwachstums unter verwendung von messungen von nt-cnp-peptiden
DE602004029680D1 (de) 2003-06-20 2010-12-02 Mayo Foundation Isoformen von gehirn-natriuretischem peptid
WO2005052593A1 (en) 2003-10-29 2005-06-09 The University Of Leicester Detection
US7431915B2 (en) 2003-10-31 2008-10-07 The Regents Of The University Of California Peptides whose uptake by cells is controllable
US8110665B2 (en) 2003-11-13 2012-02-07 Hanmi Holdings Co., Ltd. Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
JP2007531513A (ja) 2003-11-13 2007-11-08 ハンミ ファーム．インダストリー カンパニー リミテッド 薬物のキャリアとして有用なＩｇＧＦｃ断片およびその製造方法
WO2005070446A1 (en) 2004-01-15 2005-08-04 Scios Inc. Method for treating cardiac remodeling following myocardial injury
EP1730181A2 (en) 2004-01-27 2006-12-13 Compugen USA, Inc. Novel brain natriuretic peptide variants and methods of use thereof
US20080182299A1 (en) 2004-01-27 2008-07-31 Compugent Ltd. Novel brain natriuretic peptide variants and methods of use thereof
EP3620530A1 (en) 2004-03-31 2020-03-11 Kazuwa Nakao Composition for increasing body height
JP4825667B2 (ja) 2004-03-31 2011-11-30 一和 中尾 関節炎症治療剤又は予防剤
JP2005292718A (ja) 2004-04-05 2005-10-20 Furukawa Electric Co Ltd:The 光導波路、光導波路モジュールおよび光導波路の作成方法
HUE055861T2 (hu) 2004-04-21 2021-12-28 Alexion Pharma Inc Csontbejuttató konjugátumok és azok alkalmazási módszere fehérjék csonthoz kötéséhez
US20070142339A1 (en) 2004-05-10 2007-06-21 Novacea, Inc. Prevention of arterial restenosis with active vitamin d compounds
US20070081984A1 (en) * 2005-10-11 2007-04-12 Shunji Tomatsu Compositions and methods for treating hypophosphatasia
US7863238B2 (en) * 2004-06-10 2011-01-04 Saint Louis University Proteins with an attached short peptide of acidic amino acids
US7972593B2 (en) * 2004-06-10 2011-07-05 Saint Louis University Delivery of therapeutic agents to the bone
US20070081986A1 (en) * 2005-10-07 2007-04-12 Shunji Tomatsu Beta-glucuronidase with an attached short peptide of acidic amino acids
ATE496060T1 (de) 2004-07-15 2011-02-15 Univ Queensland Proteinartige verbindungen und anwendungen davon
WO2006039480A2 (en) 2004-09-29 2006-04-13 The Burnham Institute For Medical Research Tissue non-specific alkaline phosphate (tnap): a therapeutic target for arterial calcification
MX2007006524A (es) 2004-12-01 2007-06-22 Genzyme Corp Metodos para el suministro dirigido de material genetico al higado.
EP2510942B1 (en) 2005-04-07 2015-09-02 Cardiorentis AG Use of natriuretic peptide for treating heart failure
WO2006116260A2 (en) 2005-04-26 2006-11-02 Medimmune, Inc. Modulation of antibody effector function by hinge domain engineering
US20070042957A1 (en) * 2005-08-19 2007-02-22 Mayo Foundation For Medical Education And Research Type v phosphodiesterase inhibitors and natriuretic polypeptides
US7470668B2 (en) 2005-08-24 2008-12-30 Enobia Pharma Inc. Method of use of specific natriuretic peptide receptor c ligands, transgenic non-human mammals expressing specific natriuretic peptide receptor c antagonists and cells thereof
EP1933863A4 (en) 2005-09-06 2010-06-09 Zelos Therapeutics Inc PARATHYROIDIAN HORMONE ANALOGS AND METHODS USING SAME
US7803901B2 (en) * 2005-09-16 2010-09-28 Mayo Foundation For Medical Education And Research Polypeptides with natriuresis activity
WO2007041645A2 (en) 2005-10-03 2007-04-12 Scios Inc. Oxidized human bnp
RU2316334C2 (ru) 2005-12-19 2008-02-10 Медитек Индастриз ЛЛС Способ активации утраченных двигательных функций, а также определения эффективности их восстановления при повреждении центральной нервной системы
US7625564B2 (en) * 2006-01-27 2009-12-01 Novagen Holding Corporation Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo
CA2638912A1 (en) 2006-02-20 2007-08-30 Phylogica Limited Method of constructing and screening libraries of peptide structures
US8784833B2 (en) 2006-06-27 2014-07-22 Saint Louis University Prenatal enzyme replacement therapy for hypophosphatasia
WO2008053362A2 (en) 2006-06-30 2008-05-08 Interface Biologics, Inc. Bioresponsive polymers
EP2054433B1 (en) 2006-08-08 2017-12-13 Mayo Foundation For Medical Education And Research Diuretic and natriuretic polypeptides
US7825092B2 (en) 2006-08-08 2010-11-02 University Of South Florida Dendroaspis natriuretic peptide for treatment of cancer
DK2615108T3 (en) 2006-09-08 2017-01-30 Ambrx Inc Modified human plasma polypeptide or fc scaffolds and their applications
BRPI0716228A2 (pt) 2006-09-08 2013-10-15 Mayo Foundation Polipeptídeos aquaréticos e natriuréticos carecendo de atividade vasodilatadora
PE20081140A1 (es) * 2006-10-25 2008-09-22 Amgen Inc Agentes terapeuticos a base de peptidos derivados de toxinas
WO2008058016A2 (en) 2006-11-02 2008-05-15 University Of Virginia Patent Foundation Ethoid-containing compounds, methods for preparing ethoid-containing compounds, and methods for use
CN101668421B (zh) 2006-11-16 2014-05-21 凯制药公司 用于治疗甲状旁腺功能亢进和高钙血症的聚阳离子钙调节肽
US20080181903A1 (en) 2006-12-21 2008-07-31 Pdl Biopharma, Inc. Conjugate of natriuretic peptide and antibody constant region
WO2008109903A1 (en) 2007-03-12 2008-09-18 Biomedica Medizinprodukte Gmbh & Co Kg Diagnosis of septic complications
EP1985697A1 (en) 2007-04-27 2008-10-29 AM-Pharma B.V. Modified phosphatases
KR20080098216A (ko) 2007-05-04 2008-11-07 한미약품 주식회사 캐리어 물질을 이용한 나트륨 배설 펩타이드 약물 결합체
PL2158319T4 (pl) 2007-05-11 2016-04-29 Alexion Pharma Inc Fosfataza alkaliczna kierowana do kości, zestawy i zastosowanie
KR20100021601A (ko) 2007-05-14 2010-02-25 바이오겐 아이덱 엠에이 인코포레이티드 단일-쇄 Ｆｃ(ＳｃＦｃ) 부분, 이를 포함하는 결합 폴리펩타이드, 및 이에 관련된 방법
US20100310561A1 (en) 2007-06-06 2010-12-09 Boehringer Ingelheim International Gmbh Natriuretic fusion proteins
WO2008154543A2 (en) 2007-06-11 2008-12-18 Abbott Biotechnology Ltd. Methods for treating juvenile idiopathic arthritis
WO2009006520A1 (en) 2007-07-03 2009-01-08 Medimmune, Llc Hinge domain engineering
AP2009005091A0 (en) 2007-07-06 2009-12-31 Theratechnologies Inc Bifunctional fusion proteins of the alpha-melanocyte stimulating hormone (ALPHA-MSH) and atrial natriuretic protein (ANP) and uses in hypertension andacute kidney injury
AU2008279379B2 (en) 2007-07-20 2016-03-24 Mayo Foundation For Medical Education And Research Natriuretic polypeptides
US20090053192A1 (en) 2007-08-10 2009-02-26 Burnham Institute For Medical Research Tissue-nonspecific alkaline phosphatase (tnap) activators and uses thereof
CN103298935A (zh) 2007-08-15 2013-09-11 阿穆尼克斯公司 用于改善生物活性多肽性能的组合物和方法
CA2699100A1 (en) 2007-09-11 2009-04-02 Dorian Bevec Use of a peptide as a therapeutic agent
CA2699169A1 (en) 2007-09-11 2009-04-16 Mondobiotech Laboratories Ag Therapeutic uses of intermedin 47 and 53 peptides
EP2187953A2 (en) * 2007-09-11 2010-05-26 Mondobiotech Laboratories AG Use of a peptide as a therapeutic agent
CA2699073A1 (en) 2007-09-11 2009-04-02 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
AU2008297893A1 (en) 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a deslorelin and mastoparan as a therapeutic agent
ES2575397T3 (es) 2007-09-11 2016-06-28 Cardiopep Pharma Gmbh Uso de péptidos natriuréticos para el tratamiento de síndromes de angioedema
WO2009036448A2 (en) 2007-09-15 2009-03-19 Mayo Foundation For Medical Education And Research Natriuretic peptide receptor-c agonists
AU2008326327A1 (en) 2007-11-21 2009-05-28 Biomarin Pharmaceutical Inc. Variants of C-type natriuretic peptide
WO2009086126A2 (en) 2007-12-21 2009-07-09 Mayo Foundation For Medical Education And Research Natriuretic polypeptides
EP2080812A1 (en) 2008-01-18 2009-07-22 Transmedi SA Compositions and methods of detecting post-stop peptides
HRP20160303T1 (hr) 2008-05-23 2016-04-22 Daiichi Sankyo Company, Limited Peptid koji je sposoban produljiti vrijeme polu-života pogodnih peptida u plazmi
CA2727085A1 (en) 2008-06-06 2009-12-10 Mayo Foundation For Medical Education And Research Chimeric natriuretic polypeptides and methods for inhibiting cardiac remodeling
WO2009156481A1 (en) 2008-06-25 2009-12-30 Ascendis Pharma As Pegylated bnp
KR101871510B1 (ko) 2008-06-26 2018-06-26 악셀레론 파마 인코포레이티드 액티빈-ａｃｔｒｉｉａ 길항물질을 투약하는 방법 및 치료된 환자의 모니터링
EP2307447B1 (en) 2008-07-02 2016-03-09 Mayo Foundation For Medical Education And Research Natriuretic polypeptides with unique pharmacologic profiles
EP2300501B1 (en) 2008-07-23 2014-08-20 Hanmi Science Co., Ltd. A polypeptide complex comprising non-peptidyl polymer having three functional ends
US20100093678A1 (en) 2008-10-10 2010-04-15 The University Of Georgia Research Foundation, Inc Compositions and methods of the treatment of obesity and osteoporosis
US8642550B2 (en) 2008-10-24 2014-02-04 Mayo Foundation For Medical Education And Research Chimeric natriuretic peptides without hypotensive inducing capability
WO2010078325A2 (en) 2008-12-29 2010-07-08 Mayo Foundation For Medical Education And Research Natriuretic polypeptides for reducing or preventing restenosis
AR075029A1 (es) 2009-01-19 2011-03-02 Hanmi Pharm Ind Co Ltd Metodo para producir una proteina o un peptido fisiologicamente activo usando un fragmento de inmunoglobulina
JP2012521784A (ja) 2009-03-30 2012-09-20 ベーリンガー・インゲルハイム・インテルナツィオナール・ゲーエムバーハー イヌＦｃ部分を含む融合タンパク質
US20120053123A1 (en) 2009-05-05 2012-03-01 Mayo Foundation For Medical Education And Research Natriuretic polypeptides having mutations within their disulfide rings
PE20120792A1 (es) 2009-05-20 2012-07-27 Biomarin Pharm Inc Variantes de peptidos natriureticos de tipo c
BR112012027765A2 (pt) 2010-04-30 2019-09-24 Enobia Pharma Inc métodos, composições e kits para tratamento de distúrbios de mineralização da matriz.
US9266939B2 (en) 2010-12-27 2016-02-23 Alexion Pharmaceuticals, Inc. Compositions comprising natriuretic peptides and methods of use thereof
SG11201401605QA (en) 2011-10-19 2014-09-26 Alexion Pharma Holding Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
AU2012335009B2 (en) 2011-11-10 2017-08-31 Kai Pharmaceuticals, Inc. Calcimimetics and methods for their use
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
JP2015526423A (ja) 2012-07-25 2015-09-10 サイオクサス セラピューティクス リミテッド カヘキシア及びサルコペニアを治療するためのｓ−ピンドロールの使用
PT3461891T (pt) 2014-01-24 2020-07-30 Am Pharma Bv Processamento a jusante de uma fosfatase alcalina
HRP20251099T1 (hr) 2014-06-09 2025-11-07 Ultragenyx Pharmaceutical Inc. Učinkovita i djelotvorna kontrola serumskog fosfata za optimalno stvaranje kostiju
WO2016007873A1 (en) 2014-07-11 2016-01-14 The Regents Of The University Of Michigan Compositions and methods for treating craniosynostosis
CA2967851C (en) 2014-12-05 2024-02-27 Alexion Pharmaceuticals, Inc. Treating seizure with recombinant alkaline phosphatase
AU2016211447B2 (en) 2015-01-28 2021-09-23 Alexion Pharmaceuticals, Inc. Methods of treating a subject with an alkaline phosphatase deficiency
EP3337894A1 (en) 2015-08-17 2018-06-27 Alexion Pharmaceuticals, Inc. Manufacturing of alkaline phosphatases
JP6868617B2 (ja) 2015-09-28 2021-05-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド 低ホスファターゼ血症の組織非特異的アルカリホスファターゼ（ｔｎｓａｌｐ）酵素補充療法に有効な投薬計画の特定
US11400140B2 (en) 2015-10-30 2022-08-02 Alexion Pharmaceuticals, Inc. Methods for treating craniosynostosis in a patient
US11065306B2 (en) 2016-03-08 2021-07-20 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children
WO2017173395A1 (en) 2016-04-01 2017-10-05 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
KR20220162816A (ko) 2016-04-01 2022-12-08 알렉시온 파마슈티칼스, 인코포레이티드 알칼리성 포스파타아제로 근육 약화의 치료
WO2017171871A1 (en) 2016-04-01 2017-10-05 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
US10988744B2 (en) 2016-06-06 2021-04-27 Alexion Pharmaceuticals, Inc. Method of producing alkaline phosphatase
EP3474886B1 (en) 2016-06-27 2021-08-04 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children and adolescents
WO2018035420A1 (en) 2016-08-18 2018-02-22 Alexion Pharmaceuticals, Inc. Methods for treating tracheobronchomalacia

Also Published As

Publication number Publication date
DK1759001T3 (da) 2011-08-01
US7763712B2 (en) 2010-07-27
US20160052968A1 (en) 2016-02-25
EP1759001A4 (en) 2008-12-31
CA2559228A1 (en) 2005-11-03
EP1759001A1 (en) 2007-03-07
SI3404102T1 (sl) 2021-11-30
EP2348114B1 (en) 2018-07-25
EP1759001B1 (en) 2011-04-13
AU2005235635B2 (en) 2010-11-18
ES2365023T3 (es) 2011-09-20
SI2348114T1 (sl) 2018-11-30
PL2348114T3 (pl) 2019-08-30
ES2887039T3 (es) 2021-12-21
PL1759001T3 (pl) 2011-09-30
EP3404102A1 (en) 2018-11-21
US20060014687A1 (en) 2006-01-19
HUE055861T2 (hu) 2021-12-28
PT1759001E (pt) 2011-07-12
DK2348114T3 (en) 2018-09-03
WO2005103263B1 (en) 2005-12-15
DK3404102T3 (da) 2021-09-06
ES2687786T3 (es) 2018-10-29
PT3404102T (pt) 2021-09-16
JP4874954B2 (ja) 2012-02-15
AU2005235635A1 (en) 2005-11-03
CA2559228C (en) 2016-06-21
WO2005103263A1 (en) 2005-11-03
DE602005027461D1 (de) 2011-05-26
HK1255900A1 (en) 2019-08-30
JP2007533669A (ja) 2007-11-22
EP3404102B1 (en) 2021-08-11
US20190119323A1 (en) 2019-04-25
US11248021B2 (en) 2022-02-15
US10000532B2 (en) 2018-06-19
US7960529B2 (en) 2011-06-14
HUE039448T2 (hu) 2018-12-28
ATE505551T1 (de) 2011-04-15
EP2348114A1 (en) 2011-07-27
US20100221234A1 (en) 2010-09-02
PT2348114T (pt) 2018-10-18
US20100240125A1 (en) 2010-09-23

Similar Documents

Publication Publication Date Title
HUE039448T2 (hu) Csontba szállító konjugátumok és alkalmazási módszerük a fehérjék csontba juttatására
GEP20074016B (en) Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
LU91989I9 (pl)
MX2007002189A (es) Sales de dicetopiperazina, sales de dicetomorfolina o sales de dicetodioxano para suministro de farmacos.
MY148680A (en) Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
DK1259563T3 (da) Fremgangsmåde til fremstillilng af 1-benzotriazolylcarbonat-estre af vandoplöselige polymerer
AU1387002A (en) New cross-linked derivatives of hyaluronic acid
WO2005067898A3 (en) Improved sustained release compositions for pulmonary administration of insulin
WO2005117919A3 (en) Delayed-setting calcium phosphate pastes
WO2006081249A3 (en) Conjugates of biologically active proteins having a modified in vivo half-life
WO2004009774A3 (en) Protein conjugates with a water-soluble biocompatible, biogradable polymer
GB0126194D0 (en) Pharmaco-dietary preparation having a nutrition-supplementing and nutrition-enhancing effect
WO2007043048A3 (en) Self-assembled fmoc-ff hydrogels
ATE506392T1 (de) Blockcopolymer für wirkstoffkonjugate und deren pharmazeutische zusammensetzungen
DE60216305D1 (de) Zusammensetzungen zur verabreichung von arzneimittelkombinationen
WO2003045319A3 (en) Targeted therapeutics and uses thereof
IL184227A0 (en) Biologically active peptides
BR0009472A (pt) Antagonistas de lhrh com propriedades desolubilidade aperfeiçoadas
SG158856A1 (en) Controlled release compositions based on block copolymers
ITTO20000674A0 (it) Composizioni a base di aminoacidi, atte al trattamento dell'insufficienza cardiaca.
HK1094972A (en) Biologically active peptide vapeehptllteaplnpk derivatives